

Article

A Comparative Analysis of the Wound Healing-Related Heterogeneity of Adipose-Derived Stem Cells Donors

Guoqiang Ren , Qiuyue Peng , Jeppe Emmersen, Vladimir Zachar, Trine Fink  and Simone R. Porsborg * 

Regenerative Medicine Group, Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 3B, 9220 Aalborg, Denmark

* Correspondence: sriis@hst.aau.dk; Tel.: +45-9940-7567

Abstract: Adipose-derived Stem cells (ASCs) are on the verge of being available for large clinical trials in wound healing. However, for developing advanced therapy medicinal products (ATMPs), potency assays mimicking the mode of action are required to control the product consistency of the cells. Thus, greater effort should go into the design of product assays. Therefore, we analyzed three ASC-based ATMPs from three different donors with respect to their surface markers, tri-lineage differentiation, proliferation, colony-forming unit capacity, and effect on fibroblast proliferation and migration, endothelial proliferation, migration, and angiogenesis. Furthermore, the transcriptome of all three cell products was analyzed through RNA-sequencing. Even though all products met the criteria by the International Society for Cell and Gene Therapy and the International Federation for Adipose Therapeutics and Science, we found one product to be consistently superior to others when exploring their potency in the wound healing specific assays. Our results indicate that certain regulatory genes associated with extracellular matrix and angiogenesis could be used as markers of a superior ASC donor from which to use ASCs to treat chronic wounds. Having a panel of assays capable of predicting the potency of the product would ensure the patient receives the most potent product for a specific indication, which is paramount for successful patient treatment and acceptance from the healthcare system.

Keywords: adipose-derived stem cells; heterogeneity; transcriptome; wound healing; angiogenesis; extracellular matrix



Citation: Ren, G.; Peng, Q.; Emmersen, J.; Zachar, V.; Fink, T.; Porsborg, S.R. A Comparative Analysis of the Wound Healing-Related Heterogeneity of Adipose-Derived Stem Cells Donors. *Pharmaceutics* **2022**, *14*, 2126. <https://doi.org/10.3390/pharmaceutics14102126>

Academic Editor: Giuseppe De Rosa

Received: 30 August 2022

Accepted: 4 October 2022

Published: 6 October 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Chronic wounds affect millions of people worldwide; they pose a significant burden to the patients and society, and they do not follow the normal wound healing process, resulting in lengthy treatment processes, high treatment costs, and inadequate response to treatment [1,2]. The commonly used clinical treatment for chronic wounds includes inflammation control, wound dressing changing, operative debridement, and flap repair. A new and exciting alternative to the current treatment options is stem cell-based therapy, which stimulates the body's intrinsic repair mechanism to regenerate tissues and restore normal function. Human adipose-derived stem cells (ASCs), found in adipose tissue, have been acknowledged as one of the sources of clinically relevant stem cells with broad application prospects [3]. The advantages of ASCs are that they are relatively easy to obtain in large numbers from minimally-invasive liposuction procedures, they maintain their characteristics after long-term in vitro.

Culture, and they possess low immunogenicity, which enables the use of allogeneic ASCs [4–6]. ASCs have, in preclinical studies, shown great promise as a treatment modality for healing cutaneous wounds [7–9], where they have been shown to diminish inflammation [10,11], stimulate angiogenesis [12–15], and support fibroblast [12,16] and keratinocyte [12,14] growth. It has been hypothesized that ASCs exert their wound healing properties through responsiveness to their environment, leading to stimulation and modulation of the residing tissue cells through the secretion of soluble factors [17].

Large-scale production and subsequent adoption of ASC-based medicinal products require attention to better product standardization, and several production steps, from the isolation of starting material to the storage of the product, could influence the characteristics of the final product and the clinical effectiveness [18]. Indeed, production parameters, such as the use of trypsin or hypoxia, have been shown to influence several wound-healing properties, including enhanced immunosuppression [19], secretion of pro-angiogenesis growth factors [17,20–24], increased endothelial cell growth [17] and angiogenesis [21–24], re-epithelialization [25,26], and extracellular matrix (ECM) production [27]. Another major area giving rise to variation is the starting material. Several studies have identified a difference in ASCs isolated from different donors based on characteristics, such as age [28–33], sex [34,35], and body mass index (BMI) [36,37], influencing the proliferation [28,29,31], viability [29], migration [32], angiogenic [33,36], multilineage differentiation [28–30,34,37] capacity of the ASCs. Recently, ASCs isolated from aged and diabetic donors showed a reduced capacity for accelerating fibroblast migration and endothelial cell angiogenesis compared to younger donors [32]. Furthermore, it has been suggested that specific genetic profiles of individual donors may introduce a non-negligible inconsistent therapeutic effect of cells when used for clinical purposes [38].

However, no previous study has yet linked these donor characteristics to a molecular biomarker of ASCs performance in relation to specific applications, such as wound healing. A biomarker (short for molecular biomarker) is a biological indicator of a biological state or condition, as defined by World Health Organization (WHO) as “any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease” [39]. Such a marker could be used for stem cell production to ensure the selection of the donors giving rise to the most potent ASCs and thereby optimizing the chance for patients to receive the best treatment modality [18].

Therefore, in this study, we aim to identify a panel of markers to use in the future screening of ASCs for downstream production. We comprehensively characterize ASCs and their inter-donor variations based on a panel of quantitative characteristic and functional parameters, using well-established *in vitro* models [40,41], representing various wound healing processes. We link the identified differences in the effect size of the specific mode of action (MoA) to molecular targets of the mechanism of action (MeA) identified in the transcriptome of the ASCs.

2. Materials and Methods

2.1. Cell Isolation and Culture

Adipose tissue was anonymously donated by three healthy subjects undergoing cosmetic liposuction surgery at Aleris Private Hospital, Aalborg, Denmark (Gender: male, female, female; Age: 44, 53, 49; Location: abdomen, abdomen, knee; BMI: 25.4, NA, 23.6. All the donors had signed an informed consent form, and the protocol was approved by the regional committee on biomedical research ethics of Northern Jutland, Denmark (Project no. N-20160025).

ASCs were isolated, as previously described [42]. In brief, after being washed four times with sterile phosphate-buffered saline (PBS) (Invitrogen, Taastrup, Denmark), the adipose tissue was dissociated with 0.6 U/ml Collagenase NB 4 Standard Grade (Serva Electrophoresis, Heidelberg, Germany) in Hanks balanced salt solution (HBSS; Invitrogen) for 60 min at 37 °C under continuous agitation. After filtering the dissociated tissue through a 100- μ m filter (Millipore, Omaha, NE, USA) and centrifugation at 400 \times *g* for 10 min, the pellet was resuspended and filtered through a 60- μ m filter and pelleted again by centrifugation at 400 \times *g* for 10 min. The obtained cell pellet was handled and expanded in an automated bioreactor Cell Expansion system (Terumo BCT, Lakewood, CO, USA) and cryopreserved as described by Haack-Sørensen et al. [40]. For the subsequent analysis of the ASCs, the cells were thawed and cultured in T175 culture flasks (Greiner Bio-one, Frickenhausen, Germany) in alpha-Minimum Essential Medium with GlutaMAX supplemented with 10% fetal calf serum (FCS) and 100 U/ml penicillin and 0.1 mg/mL

streptomycin (all from Invitrogen), and the TrypLE (Gibco) was used to detach the cells when they reached 70–80% confluency. Hereafter, the ASC cultures were named ASC-101, ASC-105, and ASC-106 and used in passages 1–2 for subsequent procedures. For an overview of the experimental setup, see Figure 1.




Figure 1. Flowchart of the workflow process. Step A: ASCs from three donors were isolated from lipoaspirate, expanded in an automated bioreactor, and frozen. After thawing, the cells were expanded in flasks from which ASCs were harvested for characteristic tests (Step B1), and conditioned media (ASC-CM) was harvested for functional tests (Step B2). To characterize the ASC, ASCs were seeded at 8,000 cells/cm² in separate T175 culture flasks (Greiner Bio-one, Frickenhausen, Germany), cultured until 80% confluent, washed three times with PBS and then supplied with fresh culture media. After 24 h, the CM was collected, centrifugated at 400× g for 10 min, and the supernatant frozen at −80 °C.

Human Dermal Microvascular Epithelial Cells (HDMECs, Promo-cell, Heidelberg, Germany) and Human Dermal Fibroblasts (HDFs, Life Technologies, Frederick, MD, USA) were cultured following the manufacturer’s instructions.

2.2. Stem Cell Characterization

To characterize the surface marker phenotypes of the three ASC populations, multi-chromatic flow cytometry was used. The detailed protocol has been described previously by our laboratory [43]. In brief, passage 2 ASCs were stained with antibodies against the surface markers CD29, CD90, CD166, CD73, CD201, CD248, CD105, CD274, CD34, CD271, CD146, CD146, Stro-1, CD36, CD200, and CD31 for 30 minutes (BD Biosciences, Lyngby, Denmark). After washing twice with PBS, the fluorescence of the ASCs was measured by the CytoFLEX flow cytometer (Beckman Coulter, Copenhagen, Denmark) and analyzed using the Kaluza 2.1 software package (Beckman Coulter, Copenhagen, Denmark).

2.3. Trilineage Differentiation

2.3.1. Adipogenic Differentiation

The three ASC populations were seeded in 12-well tissue culture plates at 5000 cells/cm² and incubated for 2 weeks with the STEMPRO[®] Adipogenesis Differentiation Kit (ThermoFisher Scientific, Life Technologies, Roskilde, Denmark). Hereafter, the cells were fixed in 4% paraformaldehyde (AppliChem, Esbjerg, Denmark) in PBS, and the lipids were stained using Oil Red O (Sigma-Aldrich, Søborg, Denmark) for 30 min. Images of the tri-lineage differentiation were captured by standard bright field microscopy (Olympus CKX41, Life Science Solution, Ballerup, Denmark).

2.3.2. Osteogenic Differentiation

ASCs were seeded in 12-well tissue culture plates at 2500 cells/cm² and incubated for three weeks with the STEMPRO[®] Osteogenesis Differentiation Kit (ThermoFisher Scientific, Life Technologies, Roskilde, Denmark). The cells were then fixed in 4% paraformaldehyde, and the calcium deposits were stained with Alizarin Red (Sigma-Aldrich) for 30 min.

2.3.3. Chondrogenic Differentiation

ASCs were seeded in a 96-well V-shaped tissue culture plate (Greiner Bio-one, Frickenhausen, Germany) at 80,000 cells per well, centrifuged at $500\times g$ for 5 min, and incubated for 3 weeks with the STEMPRO[®] Chondrogenic-differentiation kit (ThermoFisher Scientific, Life Technologies, Roskilde, Denmark). The control pellets were maintained in a growth medium. Hereafter, the pellets were embedded in 5 μm paraffin sections, the sulfated glycosaminoglycans (GAGs) stained with Alcian Blue 8GX (Sigma-Aldrich, Søborg, Denmark) for 30 min, and the degree of differentiation was evaluated by bright field microscopy (Axio Observer).

2.4. Colony-Forming Unit

To evaluate the frequency of colony-forming unit (CFU) in the three ASC cultures, each culture was seeded in a limiting dilution assay at densities of 1–30 cells per well in a 96-well plate (Costar, Corning Life Sciences, Tewksbury, MA, USA) and cultured for 14 days with medium change twice a week. On day 14, the cells were fixed in 4% formaldehyde and stained with 0.05% Crystal Violet (Sigma Aldrich). Wells containing one or more colonies were counted, and the proportion of CFUs was assessed based on the Poisson statistics using L-Calc software (Stem Cell Technologies, Vancouver, BC, Canada).

2.5. Proliferation

To quantify the proliferation of ASCs, these were seeded with 600 cells/ cm^2 in a 96-well plate to enable the coverage of the exponential phase of the proliferating cell cultures and cultured in ASC culture medium for 13 days. To measure the effect of ASC-CM on the proliferation of HDFs and HDMECs, these were seeded in 96-well plates at a density of 600 and 15,000 cells/ cm^2 , respectively, in either ASC-CMs or a non-conditioned ASC medium (MEM) as vehicle control. The cells were hereafter cultured for 13 or 5 days, respectively, with media change every 3 days. For each cell type, cells were lysed on days 1, 3, 5, 7, 9, 11, and 13 or on days 1, 3, and 5 using 0.02% SDS (Sigma-Aldrich) for 30–40 min and frozen. The DNA content was quantified using a QUAN-IT PicoGreen kit (ThermoFisher Scientific) and a lambda DNA standard curve according to the manufacturer's protocol. The fluorescence was examined using an EnSpire multimode plate reader (PerkinElmer, Boston, MA, USA) at 485/535 nm.

2.6. Migration

Monolayers of confluent HDFs and HDMECs in 96 wells were scratched using the Wound Pin tool (V&P Scientific, Radway Green, UK) and washed with PBS to remove cell debris. The ASC-CMs were added as aforementioned, and the MEM culture medium was used as vehicle control. An inverted light microscope with a phase-contrast camera (Olympus CKX41, Life Science Solution, Ballerup, Denmark) was used to take pictures at 0, 6, and 12 h for HDFs and 0, 24, and 48 h for HDMECs, and cell migration was analyzed using the Image J software (<https://imagej.nih.gov/ij/> (accessed on 16 June 2022)).

2.7. Tube Formation

To model 3D angiogenesis, HDMECs were seeded at 10,000 cells per well in a 48-well plate coated with a 130 μL Basement Membrane Matrix (BD Biosciences, CA, USA). ASC-CM from each donor was added, and MEM was used as vehicle control. Images were captured after 4 h of incubation using a brightfield microscope and analyzed using the Image J software plugin-Angiogenesis analyzer.

2.8. RNA Sequencing

Total RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, Copenhagen, Denmark) according to the manufacturer's instructions, and RNA sequencing (RNAseq) was performed by the BGI. Europe A/S (Copenhagen, Denmark). The mRNA enrichment and purification using oligo (dT) magnetic beads and cDNA synthesis were operated,

followed by PCR amplification. Hereafter, the final library products were sequenced using BGISEQ-500. The expression levels for each gene were normalized to fragments per kilobase of exon model per million mapped reads (FPKM) using RNA-seq by Expectation-Maximization (RSEM).

The GO bioinformatics and heat map gene expression analyses were carried out using the visualization tool Dr. TOM (BGI). The upregulated or downregulated expression of genes was shown as log₂FC, which represents log-transformed fold change ($\log_2\text{FC} = \log_2[B] - \log_2[A]$), while A and B represent values of gene expression for different treatment conditions. Hereafter, the molecular targets identified from the RNAseq were thoroughly reviewed by a literature search to find existing evidence of their MeA in relation to stem cell function and wound healing, and, based upon this, narrowed down to a suggestive panel for further analysis.

2.9. Statistical Analysis

All data are presented as mean \pm SEM. The student's t-test analyzed a comparison between two groups. When comparing more than two groups, one-way or two-way ANOVA with a Bonferroni post-hoc test was used. A *p* value < 0.05 was considered statistically significant. Statistical analysis was conducted by GraphPad Prism 9 software and SPSS version 27.0.

3. Results

3.1. Identification of ASCs and Characteristic Comparison

ASCs cultures from three distinct donors were isolated, and a trilineage differentiation assay was carried out to confirm their multipotency. Histochemical analysis showed that all cultures could differentiate into both adipocytes, osteocytes, and chondrocytes (Figure 2A). The colony-forming potential was found to be higher for ASC-106 when compared to ASC-105 and ASC-101 (0.952 ± 0.027 vs. 0.363 ± 0.034 and 0.227 ± 0.02 , respectively; both *p* < 0.0001) (Figure 2B). Furthermore, the colony-forming potential of ASC-105 was found to be higher than that of ASC-101 (0.363 ± 0.034 vs. 0.227 ± 0.02 ; *p* = 0.012). The proliferative capacity of ASC-106 and ASC-105 was comparable and both prominently faster than that of ASC-101, giving rise to significantly more cells at day 13 (477.43 ± 19.52 and 376.63 ± 11.93 vs. 302.23 ± 12.63 , respectively; *p* = 0.0004 and 0.03, respectively) (Figure 2C). To evaluate the immunophenotypical profile of the ASCs, a multichromatic flow cytometry assay was performed (Figure 2D). The surface markers evaluated were categorized into five groups, based on their functionality: Mesenchymal stem cell (MSC) markers, ASC markers, differentiation capacity, immune regulation, and wound healing (Table 1). For a more detailed description of the rationale behind the selection of these markers, please refer to our previous paper [43]. The results showed that all ASC cultures were strongly positive for CD90, CD105, and CD73, recognized as the quintessential MSC markers. For the ASC marker group, all ASC cultures were positive for CD34, weakly positive for CD146, and negative for CD31, especially in ASC-101 (0.77%). In the markers relevant for ASC differentiation capacity, all ASC cultures were strongly positive for CD201 and weakly positive for CD36 and Stro-1. ASC markers connected to immune regulation showed CD29 and CD274 to be strongly positive in all ASC cultures, but CD200 was only weakly positive. In the markers related to wound healing, all ASC donors were strongly positive for CD166 and CD248 and positive for CD271.




Figure 2. Characteristic tests of adipose-derived stem cells (ASCs); (A): Histochemical analysis of Table 1. μm . (B): The colony-forming capacity (CFU, $n = 5$). (C): The proliferation of ASC cultures ($n = 3$). (D): ASCs surface markers evaluated by Flow cytometry. The data are presented as mean + SEM, * indicates a statistically significant change, $p < 0.05$. CFU, colony-forming unit.

Table 1. ASCs surface marker expression.

Function	Marker	ASC-101	ASC-105	ASC-106
MSC markers	CD105	77.73	97.65	96.43
	CD73	98.60	99.71	97.99
	CD90	99.95	99.96	99.92
	CD146	27.33	22.52	7.99
ASC markers	CD34	60.41	72.94	61.01
	CD31	0.77	2.33	7.94
	Stro-1	13.38	14.38	28.36
Differentiation capacity	CD201	98.65	96.44	98.08
	CD36	13.67	8.33	11.74
	CD29	99.99	100	99.69
Immune regulation	CD200	2.29	6.77	7.37
	CD274	94.79	92.93	60.28
	CD248	98.68	98.87	95.66
Wound healing	CD166	99.39	99.62	99.03
	CD271	59.61	24.98	23.12

MSC, Mesenchymal stem cell; ASC, adipose-derived stem cell.

3.2. Donor-Dependent Difference in ASC Function during Wound Healing

To explore the difference in performance between ASC cultures derived from the different donors, ASC-CM was produced from each culture and compared in a collection of in vitro wound healing assays based on fibroblasts and endothelial cells, mimicking suggested modes of action. Biological assays relevant to the granulation phase of wound healing were fibroblast migration and proliferation assays (Figure 3). For measuring the migration rate of fibroblasts, these were cultured to form a confluent monolayer, which was subsequently scratched and supplied with either MEM, as vehicle control, or conditioned media derived from ASC-101, -105, and -106. Hereafter, the cell-free area was measured every 6 hours until total closure was observed. For representative images of the scratch closure, see Figure 3A. The quantitative evaluation of the scratch closure revealed CM derived from ASC-106 and -105 to increase the migration of fibroblasts to a higher degree than that derived from ASC-101, resulting in significantly faster closure of the scratch ($p < 0.001$ and $= 0.03$, respectively) (Figure 3B). For evaluating the effect of ASC-CM on the proliferation of fibroblasts, they were cultured for 13 days in MEM or CM derived from ASC-101, -105, and -106, and the total DNA content evaluated every second day as a measure of total cell number. From this, it was evident that the cell number of fibroblasts cultured in CM derived from ASC-106 was significantly higher than that of fibroblasts cultured in CM from ASC-105 or -101 ($p < 0.001$ and $= 0.02$, respectively) (Figure 3C). Furthermore, CM derived from ASC-105 was found more stimulatory than that from ASC-101 ($p = 0.002$).




Figure 3. The effects of conditioned media from different ASC cultures (ASC-CM) on the migration and proliferation of dermal fibroblasts. (A): Representative images from different time points of the closure of scratched dermal fibroblasts after ASC-CM treatment in relation to the effect of unconditioned media used as vehicle control (MEM). Scalebar denotes 100 μm . (B): Quantitative assessment of the effect of ASC-CM on the development of scratch size over time ($n = 8$). The area is normalized to the starting area of each scratch. (C): The proliferation of dermal fibroblasts, quantified by the total amount of DNA, after ASC-CM treatment ($n = 3$). The data are presented as mean + SEM, * indicates a statistically significant change. $p < 0.05$. ASC, adipose-derived stem cell; MEM, Minimum Essential Media.

Assays relevant for the process of angiogenesis included endothelial proliferation, migration, and tube formation assays. When analyzing the effect of ASC-CM on the migration of endothelial cells through a scratch assay, CM derived from ASC-106 stimulated the scratch closure significantly more than that derived from ASC-105 and -101 (both $p < 0.001$) (Figure 4A,B). In accordance with this, CM from ASC-106 significantly outperformed that of ASC-105 and -101 when measuring endothelial cell proliferation (both $p < 0.001$) (Figure 4C). As a model of 3D angiogenesis, a tube formation assay was employed, and the complexity of tube networks was evaluated after 4 hours (Figure 4D). Here, it was found that CM derived from ASC-106 and ASC-105 was superior to that of ASC-101 in all measured parameters, including branching length, extreme number, node number, and junction number (Figure 4E).




Figure 4. The effects of conditioned media from different ASC cultures (ASC-CM) on migration, proliferation, and angiogenesis of human dermal microvascular endothelial cells (HDMECs). (A): Representative images of the closure of scratched HDMECs over time. Scalebar denotes 100 μm . (B): Quantification of the effect of ASC-CM on the scratch closure ($n = 8$). The scratch area is normalized to the starting size of the scratch. (C): The effect of ASCs on the HDMECs proliferation ($n = 3$). (D): Representative images of tube formation of HDMECs after ASC-CM treatment or the vehicle control; a non-conditioned ASC medium (MEM). Scalebar denotes 250 μm . (E): Quantification of the effect of ASC-CM on angiogenesis by means of the total branching length, extreme, node, and junction number ($n = 5$). The data are presented as mean + SEM, * indicates a statistically significant change, $p < 0.05$. ASC, adipose-derived stem cell.

3.3. Differences in Gene Expression between Donors and GO Analysis

Based on the characteristic and functional tests of the ASC cultures derived from distinct donors, it was found that ASC-105 and -106 might present beneficial properties in comparison to ASC-101, which might be explained by their proliferative capacity or other functional attributes. To further understand the underlying mechanism of action behind this, samples from each culture were analyzed by total RNA sequencing to explore the transcriptomic differences between these. For all three cultures, 230,487 mRNA transcripts (24,237 genes) were identified and the expression level quantified. When analyzing significantly upregulated genes ($\log_2FC \geq 1$, $Q\text{-value} \leq 0.05$) of ASC-106 and ASC-105 compared to the expression level of ASC-101, 158 genes were simultaneously upregulated in both ASC-106 and ASC-105 (Figure 5A).




Figure 5. Variability in gene expression profiles between ASC-donors (A): A Venn diagram showing the number of upregulated genes and the shared upregulated genes in ASC-105 and -106 compared to ASC-101. ($\log_2FC \geq 1$, $Q\text{ value} \leq 0.05$). (B): Gene ontology (GO) analysis of the biological process of the 158 co-upregulated genes. (C): The heatmap shows the hierarchical clustering of the 158 genes co-upregulated in ASC-105 and ASC-106 compared to ASC-101. The black box highlights the significantly upregulated genes. (D): GO analysis of the biological process of the significantly upregulated genes highlighted the heatmap. ASC, adipose-derived stem cell.

Next, gene ontology (GO) analysis of the biological processes associated with all the upregulated genes, demonstrated upregulation of 31 genes in categories relevant to wound healing, such as ECM development, angiogenesis, the proliferation and migration of cells, and stem cell development, such as cell differentiation, and the rest of the genes clustered in other categories (Figure 5B).

A separate analysis was based only on the most significantly upregulated genes, which comprised a set of 14 genes (Figure 5C). This prominent cluster of 14 genes was analyzed by GO Biological Process ontology (Figure 5D), which demonstrated that most of the 14 genes were relevant to wound healing. Jointly, these two approaches demonstrated that GO terms pertinent to wound healing, such as ECM development, angiogenesis, the proliferation and migration of cells, and stem cell development, such as cell differentiation, were among the most significantly regulated categories in ASC-106 and ASC-105 compared to ASC-101.

When analyzing the genes with a significantly higher expression in ASC-101 ($\log_2FC \geq 1$, $Q\text{-value} \leq 0.05$) compared to ASC-106 and ASC-105, several genes were found linked to processes involved in pre-adipocyte-formation or adipogenesis: *CD24*, *CDSN*, *OMD*, *ACTC1*, *COL4A5*, and *LAMB3*. This could indicate that ASC-101 was more committed toward adipogenic differentiation and thereby not as naïve as ASC-105 and ASC-106. Furthermore, the expression of *CDH6*, *COL6A6*, *ANOS1*, *TINAGL1*, *DGCR6*, *CD4*, *ADGR1*, *CLCA2*, *ACTG2*, *FOXF1*, *ECM2*, *ACAN*, *PECAM1*, *TNXB*, and *COL14A1* linked to processes involved in cell adhesion, ECM organization, and mesenchyme migration, were higher in ASC-101 (data not shown).

3.4. Selection of Putative Markers Predicting Wound Healing Capacity

To select the most promising markers predicting wound healing capacity, putative predictors were selected based on the analyses above (Figure 6). In summary, from the pool of 230,487 mRNA transcripts (24,237 genes), 158 genes (Table S1) upregulated in both ASC-105 and -106 compared to ASC-101 were identified (Figure 5A). Next, a combination of the two different analytical approaches were used to select genes of interest among the upregulated genes. From the first approach based on the gene ontology (GO) analysis of all genes (Figure 5B), 31 genes associated with wound-healing-related processes were selected. From the second approach based on the heat map analysis, we identified the 14 most significantly upregulated genes (Figure 5C). Interestingly, between these two approaches, there was an overlap of 10 genes, leading to a total of 35 unique genes (Table 2). Based on a thorough literature review of the 35 genes, we further narrowed the list down to 10 genes of special interest comprising transcription factors (TBX1, EPAS1), membrane proteins (FGFR2, ITGB8, GREM1), and secreted proteins (MMP1, MMP9, COL4A4, FGF9, and CCL11).




Figure 6. Outline of the selection process of putative markers predictive of wound healing capacity. RNA-seq, Ribonucleic acid sequencing; ASC, adipose derived stem cell.

Table 2. Enriched biological processes based on gene ontology terms for co-upregulated genes of ASC-105 and ASC-106 compared to ASC-101, with Q-value < 0.05.

Description	Gene	Go Term
ECM and tissue development		
Cell adhesion	<i>TENM2, HAPLN1, SVEP1, PCDHB3, PGM5, CADM3, PCDHB2, SPON1, EFS, CCL11, LZTS1, ITGB8, CELSR1, NUAK1, PDZD2, ITGA11, PCDH19</i>	GO:0007155
Cell-matrix adhesion	<i>ITGB8, ITGA11</i>	GO:0007160
ECM	<i>MMP1, LOC102724770-DGCR6, COL4A4, HAPLN1, RARRES2,</i>	GO:0031012
ECM disassembly	<i>MMP1</i>	GO:0022617
ECM organization	<i>MMP9, TNFRSF11B, COL10A1, COL11A1, ITGB8, ITGA11</i>	GO:0030198
Extracellular region	<i>ADA2</i>	GO:0005576
Collagen-containing extracellular matrix	<i>MMP9, COL10A1</i>	GO:0062023
Collagen fibril organization	<i>COL11A1</i>	GO:0030199
Collagen catabolic process	<i>MMP1</i>	GO:0030574
Angiogenesis development		
Angiogenesis	<i>FGF9, TBX1, FGFR4, GREM1, FGFR2, EPAS1, PTPRB</i>	GO:0001525
Positive regulation of angiogenesis	<i>PIK3R6, GREM1, CCL11, ITGB8</i>	GO:0045766
Endothelial cell morphogenesis	<i>COL4A4</i>	GO:0001886
Blood vessel morphogenesis/development	<i>TBX1</i>	GO:0048514
Blood vessel remodeling	<i>EPAS1</i>	GO:0001974
Differentiation		
Cell differentiation	<i>FGF9, RARRES2, FGFR4, FGFR2, EPAS1</i>	GO:0030154
Epithelial cell differentiation	<i>TBX1</i>	GO:0030855
Positive regulation of fat cell differentiation	<i>RARRES2</i>	GO:0045600
Osteoblast differentiation	<i>FGF9, FGFR2, ITGA11</i>	GO:0001649 GO:0045667
Mesenchymal cell differentiation	<i>FGFR2</i>	GO:0048762
Proliferation		
Positive regulation of cell proliferation	<i>TBX1, FGF9, TNFRSF11B, FGFR4, GREM1, NUAK1</i>	GO:0008284
Positive regulation of mesenchymal cell proliferation	<i>TBX1, FGFR2</i>	GO:0002053
Positive regulation of epithelial cell proliferation	<i>TBX1, FGF9, FGFR2</i>	GO:0050679
Positive regulation of endothelial cell proliferation	<i>CCL11</i>	GO:0001938
Migration		
Positive regulation of cell migration	<i>MMP9, FGFR4, EFS, CCL11</i>	GO:0030335 GO:0016477
Positive regulation of keratinocyte migration	<i>MMP9</i>	GO:0051549
Endothelial cell migration	<i>GREM1</i>	GO:0043542
Cell migration involved in sprouting angiogenesis	<i>GREM1, SLIT2</i>	GO:0002042
Others		
Wound healing	<i>FGFR2, CELSR1</i>	GO:0042060
Chondrocyte development	<i>COL11A1</i>	GO:0002063

ASC, adipose-derived stem cell; ECM, Extracellular matrix.

4. Discussion

In recent years, stem cell-based therapies are slowly gaining ground in routine medical care due to their capability to repair or replace damaged tissue, as a result of their natural ability to produce cytokines and other molecules, especially in skin wound management. ASCs, as one of the clinically most promising stem cell types, have been put in the spotlight in a broad range of clinical studies as a treatment modality for healing cutaneous wounds (clinicaltrials.gov, NCT01932021, NCT02099500, NCT02092870, NCT02314416,

NCT02394873). A series of preclinical studies have shown variability between ASCs derived from different donors in terms of proliferation and trilineage differentiation capacity [29–31,34,41]. Thus, to strengthen the success rate of implantation and treatment effect for later clinical use, the therapeutic potential of ASCs in terms of wound healing and their inter-donor variations need to be explored in more detail. In this study, we investigated the heterogeneity of ASC from different donors based on a set of characteristic and functional assays related to stem cell characteristics and their mode of action within wound healing. Additionally, to get closer to the mechanism of action, we examined the regulation of genes involved in these processes. Our results indicate that specific regulatory genes associated with ECM and angiogenesis could be used as markers of a superior ASC donor from which to use ASCs to treat chronic wounds.

When characterizing the ASCs from the three distinct donors, our approach was based on the criteria suggested in the position statement from the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) [42]. The ASCs from all donors had the capability to undergo tri-lineage differentiation, had a high proportion of CFUs and were capable of proliferating. Furthermore, all three cultures were positive for the characteristic markers CD105, CD73, CD90, and our selected ASC-markers CD146 and CD34. Moreover, a very low expression of CD31 was seen. However, it was evident that both ASC-105 and -106 had a higher proliferation rate and proportion of CFU when compared to ASC-101. It could therefore be suspected that ASC-105 and -106 could have a higher potency than ASC-101. When analyzing the transcriptome of the three ASC cultures, several transcripts giving rise to membrane-bound proteins were identified. The transcripts of fibroblast growth factor receptor 2 (*FGFR2*), integrin subunit beta 8 (*ITGB8*), and protein tyrosine phosphatase receptor type B (*PTPRB*) were enriched in both ASC-105 and -106 when compared to ASC-101. *FGFR2* is a member of the fibroblast growth factor receptor family and generally plays a vital role in stimulating angiogenesis by binding with FGF2, promoting keratinocytes proliferation and the regulation of osteoblast differentiation, proliferation, and apoptosis [43–45]. In ASCs, FGF2 has been linked to promoting the proliferation ability of hASCs via Src activation [46]. *ITGB8* is a member of the integrin beta chain family and plays a role in cell migration and cell–cell and cell–ECM adhesion [47–49]. In addition, *ITGB8* is a receptor for fibronectin, which plays a significant role in cell growth, migration, adhesion, and differentiation, and facilitates wound healing [50]. Specifically for mesenchymal stem cells, *ITGB8* has been shown to promote chondrogenic differentiation [51] and has been found differentially expressed in ASCs from different donors [32]. *PTPRB*, a member of the protein tyrosine phosphatase (PTP) family, is an enzyme mainly expressed in endothelial cells essential for blood vessel remodeling and angiogenesis [49]. In ASCs, it has been linked to reduced adipocyte differentiation [52]. Moreover, the transcripts T-box transcription factor 1 (*TBX1*) and endothelial PAS domain-containing protein 1 (*EPAS1*) were identified, both giving rise to transcription factors. *TBX1* is essential in forming tissues and organs during embryonic development [53]. Likewise, *TBX1* has been identified as a novel regulator of energy homeostasis, metabolic signaling, and adipocyte growth, development, and differentiation. However, exactly how *TBX1* regulates metabolic signaling in subcutaneous adipose tissue is still not fully elucidated. It could be through direct DNA binding and/or through off-DNA protein-protein interactions [54]. *EPAS1*, also well-known as hypoxia-inducible factor-2alpha (*HIF-2 α*), is involved in the induction of oxygen-regulated genes. It has been noted to contribute to regulating stem cell function and differentiation through activation of Oct-4 [55]. Besides, *EPAS1* (*HIF-2 α*) has been verified to facilitate the preservation of stemness and to promote stem cell proliferation of human placenta-derived mesenchymal stem cells [56].

When analyzing the functionality of the ASCs, assays relevant for both the granulation tissue and angiogenesis were included. For the formation of granulation tissue, we evaluated the inter-donor variability using fibroblast proliferation and migration assays. Fibroblasts play a vital role in the proliferation phase of wound healing by proliferating

and migrating to the wounded area. We found that conditioned mediums from ASC-106 and 105 were superior to ASC-101 for both accelerating fibroblast proliferation and migration. To identify the molecules involved in this variability, RNA sequencing and subsequent GO analysis of the biological process common for the co-upregulated genes revealed *FGF9*, *GREM1*, and *CCL11* to be enriched in relation to the wound healing GO term. *FGF9* has been shown to increase fibroblast migratory capacities [57]. In addition, *GREM1* encoding gremlin-1 is a member of the BMP (bone morphogenic protein) antagonist family. Gremlin-1 has been demonstrated to promote the proliferation of intestinal fibroblasts [58]. Likewise, overexpression of Gremlin-1 has been shown to entail TGF- β pathway elevated ECM production and myofibroblast transition [59–61]. *CCL11*, encoding C-C motif chemokine 11, also known as eotaxin-1, facilitate the migration and proliferation of lung fibroblasts [62]. Furthermore, fibroblasts synthesize and modulate the ECM components. These create a scaffolding-like structure, providing the structural integrity for the formation of granulation tissue and supporting adhesion and migration of cells as macrophages, endothelial cells, and fibroblasts [63,64]. In this study, RNA sequencing and subsequent GO analysis of the biological process typical for the co-upregulated genes also revealed *MMP1* and *MMP9* to be partially co-upregulated. It has formerly been found that *MMP9* stimulates dermal fibroblast migration [65] and contributes to synovial fibroblast proliferation and migration [66]. *MMP9* also facilitates cell migration by degrading collagen type IV, thereby breaking down the basement membrane [67]. *MMP1* usually plays a role in wound healing by promoting keratinocyte migration on fibrillar collagen, but it has been found to contribute to lung fibroblast migration in epithelial cells [68,69]. However, these genes have also been linked to fibrosis and dysregulation of the wound healing response, emphasizing the importance of a controlled regulation of these [70–72].

For angiogenesis, we found evidence of both direct and indirect mechanisms of action. As a direct measure of angiogenesis, the effect of ASCs from different donors on endothelial cell proliferation, migration, and tube formation was used. Overall, our data showed that CM from ASC-106 and 105 possessed a superior ability compared to CM from ASC-101 to promote both endothelial cell proliferation, migration, and angiogenesis. Previous work showed that ASCs from leaner-weight donors showed a higher angiogenic potential than heavier ones [36]. When diving into the underlying mechanism of action behind these effects, RNA sequencing and subsequent GO analysis of the biological process for the co-upregulated genes found evidence supporting this phenomenon. The gene expression of the superior ASCs, ASC-106 and 105, were enriched within processes of angiogenesis, endothelial cell proliferation, and endothelial cell migration regulation. Among the enriched genes was *FGF9* and the lack of *FGF9* in vivo has been verified to decrease angiogenesis [73]. In general, FGF family members have shown an essential role in wound healing, as evidenced by stimulating angiogenesis [73–78]. Furthermore, a significant increase was found in Gremlin 1 (*GRME1*), which is involved in angiogenesis-modulating in endothelial cells, endothelial cell migration, and cell migration involved in sprouting angiogenesis [79,80]. Another interesting gene upregulated is *CCL11*, a direct mediator of angiogenesis, as evidenced by its ability to induce in vitro endothelial cell proliferation, migration, and angiogenesis [81,82].

An indirect influence of ASCs on the process of angiogenesis could be through the regulation of ECM. The ECM not only provides a scaffold to support the formation of connective tissue but also plays a crucial role in angiogenesis by supporting the migration of endothelial cells to form new blood vessels in the wound bed [83]. In this study, we found a significant upregulation in ASC-105 and -106 of several ECM-relevant genes, including *MMP1*, *MMP9*, and *COL4A4*, which have all been shown to play an important role in angiogenesis. In support of this, studies found that MMP-mediated ECM degradation by ASCs accelerates the angiogenesis of endothelial cells [84,85]. *MMP1* has been found to trigger vascular remodeling and angiogenesis in the wound healing process by increasing the expression of the vascular endothelial growth factor receptor 2 (VEGFR2) and endothelial cell proliferation [86]. *MMP9* has been validated to increase the secretion

of VEGF from endothelial cells, accelerate endothelial cell migration and stimulate vessel growth [87]. *COL4A4* encodes the alpha4 (IV) chain of type IV collagen. Type IV collagen is an essential component of the endothelial basement membrane to support the formation of blood vessels and contributes to endothelial cell migration [88,89]. Additionally, it has been proven to facilitate the new microvascular elongation and survival in a dose-dependence manner in an ex vivo aortic ring model [90]. These upregulated genes could putatively be potential screening markers for ASCs with superior performance in relation to angiogenesis in wound healing.

When analyzing the inter-donor variation of ASCs from the perspective of wound healing, angiogenesis and ECM-relevant processes and genes were the main groups enriched. Based on their biological significance and the level of existing evidence, we propose a panel of stem cell- and wound healing-related genes, especially related to ECM and angiogenesis, to further validate the future screening of ASC-based medicinal products for wound healing. The suggested panel comprises *MMP1*, *MMP9*, *COL4A4*, *ITGB8*, *TBX1*, *EPAS1*, *FGFR2*, *FGF9*, *GREM1*, and *CCL11*. However, it should be mentioned that any of the 35 genes identified could hold the potential as a marker of potency. Furthermore, it should be noted that this study has examined the ASC-donor variability in vitro and by RNA-Seq technology used only to draw attention to the differences in the gene expression in ASCs from different donors, which could be used to explain the observed difference in effect. Therefore, multiple validations and further studies based on in vivo assays are required to shed more light on the biological difference between donors in wound healing and to fully validate these markers to be directly linked to the mechanism of action of ASCs in wound healing. Ultimately, the goal would be to identify markers predictive of the wound healing capacity of a stem cell preparation in a clinical setting, such that those markers could be used as potency assays. The importance of developing validated potency assays is underscored by the fact that both the European Medicines Agency (EMA) and the U.S Food and Drug Administration require such assays as part of the release criteria after transitioning from early phase trials to an approved medicinal product.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/pharmaceutics14102126/s1>, Table S1: The up-regulated gene information.

Author Contributions: Conceptualization, G.R. and S.R.P.; methodology, G.R. and Q.P.; software, G.R. and Q.P.; validation, G.R. and S.R.P.; formal analysis, G.R. and Q.P.; investigation, G.R., Q.P. and S.R.P.; resources, J.E., T.F. and V.Z.; data curation, G.R., Q.P. and S.R.P.; writing—original draft preparation, G.R.; writing—review and editing, J.E., T.F., V.Z. and S.R.P.; visualization, G.R. and S.R.P.; supervision, J.E., T.F., V.Z. and S.R.P.; project administration, S.R.P.; funding acquisition, S.R.P. All authors have read and agreed to the published version of the manuscript.

Funding: This project was funded by the Danish Diabetes Association.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the regional committee on biomedical research ethics in Northern Jutland (N-20160025, 5 April 2016).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments: The China Scholarship Council and S.C. Van Fonden are acknowledged for financial support to the first author.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Menke, N.B.; Ward, K.R.; Witten, T.M.; Bonchev, D.G.; Diegelmann, R.F. Impaired wound healing. *Clin. Dermatol.* **2007**, *25*, 19–25. [[CrossRef](#)]
2. Gosain, A.; DiPietro, L.A. Aging and Wound Healing. *World J. Surg.* **2004**, *28*, 321–326. [[CrossRef](#)]
3. Zuk, P.A.; Zhu, M.; Ashjian, P.; De Ugarte, D.A.; Huang, J.I.; Mizuno, H.; Alfonso, Z.C.; Fraser, J.K.; Benhaim, P.; Hedrick, M.H. Human adipose tissue is a source of multipotent stem cells. *Mol. Biol. Cell* **2002**, *13*, 4279–4295. [[CrossRef](#)] [[PubMed](#)]
4. Hu, L.; Zhao, J.; Liu, J.; Gong, N.; Chen, L.; Margolis, D.J.; Bartus, C.; Hoffstad, O.; Malay, S.; Berlin, J.A.; et al. Adipose tissue-derived stem cells in clinical applications. *Expert Opin. Biol. Ther.* **2013**, *13*, 1357–1370.
5. Cherubino, M.; Rubin, J.P.; Miljkovic, N.; Kelmendi-Doko, A.; Marra, K.G. Adipose-derived stem cells for wound healing applications. *Ann. Plast. Surg.* **2011**, *66*, 210–215. [[CrossRef](#)]
6. Zuk, P. Adipose-Derived Stem Cells in Tissue Regeneration: A Review. *ISRN Stem Cells* **2013**, *2013*, 713959. [[CrossRef](#)]
7. Isakson, M.; de Blacam, C.; Whelan, D.; McArdle, A.; Clover, A.J.P. Mesenchymal Stem Cells and Cutaneous Wound Healing: Current Evidence and Future Potential. *Stem Cells Int.* **2015**, *2015*, 831095. [[CrossRef](#)] [[PubMed](#)]
8. Zamora, D.O.; Natesan, S.; Becerra, S.; Wrice, N.; Chung, E.; Suggs, L.J.; Christy, R.J. Enhanced wound vascularization using a dsASCs seeded FPEG scaffold. *Angiogenesis* **2013**, *16*, 745–757. [[CrossRef](#)]
9. Zografou, A.; Papadopoulos, O.; Tsigris, C.; Kavantzias, N.; Michalopoulos, E.; Chatzistamatiou, T.; Papassavas, A.; Stavropoulou-Gioka, C.; Dontas, I.; Perrea, D. Autologous Transplantation of Adipose-Derived Stem Cells Enhances Skin Graft Survival and Wound Healing in Diabetic Rats. *Ann. Plast. Surg.* **2013**, *71*, 225–232. [[CrossRef](#)]
10. Khairoun, M.; Korevaar, S.S.; Roemeling-van Rhijn, M.; Khairoun, M.; Korevaar, S.; Lievers, E.; Leuning, D.; Ijzermans, J.; Betjes, M.; Genever, P.; et al. Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive In vitro and in a Humanized Allograft Rejection Model. *J. Stem Cell Res.* **2013**, *1* (Suppl. S6), 20780. [[CrossRef](#)] [[PubMed](#)]
11. Cao, G.; Chen, B.; Zhang, X.; Chen, H. Human Adipose-Derived Mesenchymal Stem Cells-Derived Exosomal microRNA-19b Promotes the Healing of Skin Wounds Through Modulation of the CCL1/TGF- β Signaling Axis. *Clin. Cosmet. Investig. Dermatol.* **2020**, *13*, 957–971. [[CrossRef](#)]
12. Lu, Y.; Wen, H.; Huang, J.; Liao, P.; Liao, H.; Tu, J.; Zeng, Y. Extracellular vesicle-enclosed miR-486-5p mediates wound healing with adipose-derived stem cells by promoting angiogenesis. *J. Cell. Mol. Med.* **2020**, *24*, 9590–9604. [[CrossRef](#)]
13. Moon, M.H.; Kim, S.Y.; Kim, Y.J.; Kim, S.J.; Lee, J.B.; Bae, Y.C.; Sung, S.M.; Jung, J.S. Human Adipose Tissue-Derived Mesenchymal Stem Cells Improve Postnatal Neovascularization in a Mouse Model of Hindlimb Ischemia. *Cell. Physiol. Biochem.* **2006**, *17*, 279–290. [[CrossRef](#)] [[PubMed](#)]
14. Seo, E.; Lim, J.S.; Jun, J.B.; Choi, W.; Hong, I.S.; Jun, H.S. Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing. *J. Transl. Med.* **2017**, *15*, 35. [[CrossRef](#)] [[PubMed](#)]
15. Brett, E.; Zielins, E.R.; Chin, M.; Januszyk, M.; Blackshear, C.P.; Findlay, M.; Momeni, A.; Gurtner, G.C.; Longaker, M.T.; Wan, D.C. Isolation of CD248-expressing stromal vascular fraction for targeted improvement of wound healing. *Wound Repair Regen.* **2017**, *25*, 414–422. [[CrossRef](#)]
16. Hu, L.; Wang, J.; Zhou, X.; Xiong, Z.; Zhao, J.; Yu, R.; Huang, F.; Zhang, H.; Chen, L. Exosomes derived from human adipose mesenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts. *Sci. Rep.* **2016**, *6*, 32993. [[CrossRef](#)]
17. Rehman, J.; Traktuev, D.; Li, J.; Merfeld-Clauss, S.; Temm-Grove, C.J.; Bovenkerk, J.E.; Pell, C.L.; Johnstone, B.H.; Considine, R.V.; March, K.L. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. *Circulation* **2004**, *109*, 1292–1298. [[CrossRef](#)]
18. Riis, S.; Zachar, V.; Boucher, S.; Vemuri, M.C.; Pennisi, C.P.; Fink, T. Critical steps in the isolation and expansion of adipose-derived stem cells for translational therapy. *Expert Rev. Mol. Med.* **2015**, *17*, e11. [[CrossRef](#)] [[PubMed](#)]
19. Roemeling-Van Rhijn, M.; Mensah, F.K.F.; Korevaar, S.S.; Leijts, M.J.; Van Osch, G.J.V.M.; Ijzermans, J.N.M.; Betjes, M.G.H.; Baan, C.C.; Weimar, W.; Hoogduijn, M.J. Effects of Hypoxia on the Immunomodulatory Properties of Adipose Tissue-Derived Mesenchymal Stem cells. *Front. Immunol.* **2013**, *4*, 203. [[CrossRef](#)] [[PubMed](#)]
20. Rasmussen, J.G.; Riis, S.E.; Frøbert, O.; Yang, S.; Kastrup, J.; Zachar, V.; Simonsen, U.; Fink, T. Activation of Protease-Activated Receptor 2 Induces VEGF Independently of HIF-1. *PLoS ONE* **2012**, *7*, e46087. [[CrossRef](#)]
21. Thangarajah, H.; Vial, I.N.; Chang, E.; El-Ftesi, S.; Januszyk, M.; Chang, E.I.; Paterno, J.; Neofytou, E.; Longaker, M.T.; Gurtner, G.C. IFATS Collection: Adipose Stromal Cells Adopt a Proangiogenic Phenotype Under the Influence of Hypoxia. *Stem Cells* **2009**, *27*, 266–274. [[CrossRef](#)]
22. Rubina, K.; Kalinina, N.; Efimenko, A.; Lopatina, T.; Melikhova, V.; Tsokolaeva, Z.; Sysoeva, V.; Tkachuk, V.; Parfyonova, Y. Adipose stromal cells stimulate angiogenesis via promoting progenitor cell differentiation, secretion of angiogenic factors, and enhancing vessel maturation. *Tissue Eng. Part A* **2009**, *15*, 2039–2050. [[CrossRef](#)]
23. Efimenko, A.; Starostina, E.; Kalinina, N.; Stolzing, A. Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. *J. Transl. Med.* **2011**, *9*, 10. [[CrossRef](#)]
24. Liu, L.; Gao, J.; Yuan, Y.; Chang, Q.; Liao, Y.; Lu, F. Hypoxia preconditioned human adipose derived mesenchymal stem cells enhance angiogenic potential via secretion of increased VEGF and bFGF. *Cell Biol. Int.* **2013**, *37*, 551–560. [[CrossRef](#)]
25. Lee, H.C.; An, S.G.; Lee, H.W.; Park, J.-S.; Cha, K.S.; Hong, T.J.; Park, J.H.; Lee, S.Y.; Kim, S.-P.; Kim, Y.D.; et al. Safety and Effect of Adipose Tissue-Derived Stem Cell Implantation in Patients With Critical Limb Ischemia. *Circ. J.* **2012**, *76*, 1750–1760. [[CrossRef](#)]

26. Riis, S.; Newman, R.; Ipek, H.; Andersen, J.I.; Kuninger, D.; Boucher, S.; Vemuri, M.C.; Pennisi, C.P.; Zachar, V.; Fink, T. Hypoxia enhances the wound-healing potential of adipose-derived stem cells in a novel human primary keratinocyte-based scratch assay. *Int. J. Mol. Med.* **2017**, *39*, 587–594. [[CrossRef](#)]
27. Riis, S.; Stensballe, A.; Emmersen, J.; Pennisi, C.P.; Birkelund, S.; Zachar, V.; Fink, T. Mass spectrometry analysis of adipose-derived stem cells reveals a significant effect of hypoxia on pathways regulating extracellular matrix. *Stem Cell Res. Ther.* **2016**, *7*, 52. [[CrossRef](#)]
28. Alt, E.U.; Senst, C.; Murthy, S.N.; Slakey, D.P.; Dupin, C.L.; Chaffin, A.E.; Kadowitz, P.J.; Izadpanah, R. Aging alters tissue resident mesenchymal stem cell properties. *Stem Cell Res.* **2012**, *8*, 215–225. [[CrossRef](#)] [[PubMed](#)]
29. Choudhery, M.S.; Badowski, M.; Muise, A.; Pierce, J.; Harris, D.T. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. *J. Transl. Med.* **2014**, *12*, 8. [[CrossRef](#)]
30. De Girolamo, L.; Lopa, S.; Arrigoni, E.; Sartori, M.F.; Baruffaldi Preis, F.W.; Brini, A.T. Human adipose-derived stem cells isolated from young and elderly women: Their differentiation potential and scaffold interaction during in vitro osteoblastic differentiation. *Cytotherapy* **2009**, *11*, 793–803. [[CrossRef](#)]
31. Van Harmelen, V.; Röhrig, K.; Hauner, H. Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. *Metabolism* **2004**, *53*, 632–637. [[CrossRef](#)] [[PubMed](#)]
32. Ren, S.; Xiong, H.; Chen, J.; Yang, X.; Liu, Y.; Guo, J.; Jiang, T.; Xu, Z.; Yuan, M.; Liu, Y.; et al. The whole profiling and competing endogenous RNA network analyses of noncoding RNAs in adipose-derived stem cells from diabetic, old, and young patients. *Stem Cell Res. Ther.* **2021**, *12*, 313. [[CrossRef](#)]
33. De Barros, S.; Dehez, S.; Arnaud, E.; Barreau, C.; Cazavet, A.; Perez, G.; Galinier, A.; Casteilla, L.; Planat-Bénard, V. Aging-related decrease of human ASC angiogenic potential is reversed by hypoxia preconditioning through ROS production. *Mol. Ther.* **2013**, *21*, 399–408. [[CrossRef](#)]
34. Aksu, A.E.; Rubin, J.P.; Dudas, J.R.; Marra, K.G. Role of gender and anatomical region on induction of osteogenic differentiation of human adipose-derived stem cells. *Ann. Plast. Surg.* **2008**, *60*, 306–322. [[CrossRef](#)] [[PubMed](#)]
35. Ogawa, R.; Mizuno, H.; Watanabe, A.; Migita, M.; Hyakusoku, H.; Shimada, T. Adipogenic differentiation by adipose-derived stem cells harvested from GFP transgenic mice-Including relationship of sex differences. *Biochem. Biophys. Res. Commun.* **2004**, *319*, 511–517. [[CrossRef](#)]
36. Juntunen, M.; Heinonen, S.; Huhtala, H.; Rissanen, A.; Kaprio, J.; Kuismanen, K.; Pietiläinen, K.H.; Miettinen, S.; Patrikoski, M. Evaluation of the effect of donor weight on adipose stromal/stem cell characteristics by using weight-discordant monozygotic twin pairs. *Stem Cell Res. Ther.* **2021**, *12*, 516. [[CrossRef](#)]
37. Mohiuddin, O.A.; Motherwell, J.M.; Rogers, E.; Bratton, M.R.; Zhang, Q.; Wang, G.; Bunnell, B.; Hayes, D.J.; Gimble, J.M. Characterization and Proteomic Analysis of Decellularized Adipose Tissue Hydrogels Derived from Lean and Overweight/Obese Human Donors. *Adv. Biosyst.* **2020**, *4*, e2000124. [[CrossRef](#)]
38. Stroncek, D.F.; Jin, P.; Wang, E.; Jett, B.; Zielins, E.R.; Atashroo, D.A.; Maan, Z.N.; Duscher, D.; Walmsley, G.G.; Hu, M.; et al. Potency analysis of cellular therapies: The emerging role of molecular assays. *J. Transl. Med.* **2016**, *5*, 24. [[CrossRef](#)] [[PubMed](#)]
39. Nations, U.; Programme, E.; Criteria, E.H.; Management, S.; Programme, T.I.; Safety, C.; Co-operation, E.; Organizations, P.; Conference, U.N.; Library, W.H.O.; et al. *Biomarkers in Risk Assessment: Validity and Validation*; WHO: Geneva, Switzerland, 2014; pp. 1–21.
40. Haack-Sørensen, M.; Juhl, M.; Follin, B.; Harary Søndergaard, R.; Kirchoff, M.; Kastrup, J.; Ekblond, A. Development of large-scale manufacturing of adipose-derived stromal cells for clinical applications using bioreactors and human platelet lysate. *Scand. J. Clin. Lab. Investig.* **2018**, *78*, 293–300. [[CrossRef](#)] [[PubMed](#)]
41. Mohamed-Ahmed, S.; Fristad, I.; Lie, S.A.; Suliman, S.; Mustafa, K.; Vindenes, H.; Idris, S.B. Adipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison. *Stem Cell Res. Ther.* **2018**, *9*, 168. [[CrossRef](#)] [[PubMed](#)]
42. Bourin, P.; Bunnell, B.A.; Casteilla, L.; Dominici, M.; Katz, A.J.; March, K.L.; Redl, H.; Rubin, J.P.; Yoshimura, K.; Gimble, J.M. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics (IFATS) and Science and the International Society for Cellular Therapy (ISCT). *Cytotherapy* **2013**, *15*, 641.
43. Wu, X.Y.; Xu, H.; Wu, Z.F.; Chen, C.; Liu, J.Y.; Wu, G.N.; Yao, X.Q.; Liu, F.K.; Li, G.; Shen, L. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. *Oncotarget* **2015**, *6*, 44563. [[CrossRef](#)]
44. Xu, N.; Brodin, P.; Wei, T.; Meisgen, F.; Eidsmo, L.; Nagy, N.; Kemeny, L.; Stähle, M.; Sonkoly, E.; Pivarcsi, A. MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2. *J. Investig. Dermatol.* **2011**, *131*, 1521–1529. [[CrossRef](#)] [[PubMed](#)]
45. Kaabeche, K.; Lemonnier, J.; Le Mée, S.; Caverzasio, J.; Marie, P.J. Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation. *J. Biol. Chem.* **2004**, *279*, 36259–36267. [[CrossRef](#)]
46. Ma, Y.; Kakudo, N.; Morimoto, N.; Lai, F.; Taketani, S.; Kusumoto, K. Fibroblast growth factor-2 stimulates proliferation of human adipose-derived stem cells via Src activation. *Stem Cell Res. Ther.* **2019**, *10*, 350. [[CrossRef](#)] [[PubMed](#)]
47. Moyle, M.; Napier, M.A.; McLean, J.W. Cloning and expression of a divergent integrin subunit beta 8. *J. Biol. Chem.* **1991**, *266*, 19650–19658. [[CrossRef](#)]

48. Mu, D.; Cambier, S.; Fjellbirkeland, L.; Baron, J.L.; Munger, J.S.; Kawakatsu, H.; Sheppard, D.; Courtney Broaddus, V.; Nishimura, S.L. The integrin $\alpha(v)\beta_8$ mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF- β_1 . *J. Cell Biol.* **2002**, *157*, 493–507. [[CrossRef](#)]
49. Gaudet, P.; Livstone, M.S.; Lewis, S.E.; Thomas, P.D. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. *Brief. Bioinform.* **2011**, *12*, 449–462. [[CrossRef](#)]
50. Pankov, R.; Yamada, K.M. Fibronectin at a glance. *J. Cell Sci.* **2002**, *115*, 3861–3863. [[CrossRef](#)]
51. LaPointe, V.L.S.; Verpoorte, A.; Stevens, M.M. The Changing Integrin Expression and a Role for Integrin β_8 in the Chondrogenic Differentiation of Mesenchymal Stem Cells. *PLoS ONE* **2013**, *8*, e82035. [[CrossRef](#)]
52. Kim, J.S.; Kim, W.K.; Oh, K.J.; Lee, E.W.; Han, B.S.; Lee, S.C.; Bae, K.H. Protein Tyrosine Phosphatase, Receptor Type B (PTPRB) Inhibits Brown Adipocyte Differentiation through Regulation of VEGFR2 Phosphorylation. *J. Microbiol. Biotechnol.* **2019**, *29*, 645–650. [[CrossRef](#)] [[PubMed](#)]
53. Bollag, R.J.; Siegfried, Z.; Cebra-Thomas, J.A.; Garvey, N.; Davison, E.M.; Silver, L.M. An ancient family of embryonically expressed mouse genes sharing a conserved protein motif with the T locus. *Nat. Genet.* **1994**, *7*, 383–389. [[CrossRef](#)]
54. Markan, K.R.; Boland, L.K.; King-McAlpin, A.Q.; Claflin, K.E.; Leaman, M.P.; Kemerling, M.K.; Stonewall, M.M.; Amendt, B.A.; Ankrum, J.A.; Potthoff, M.J. Adipose TBX1 regulates β -adrenergic sensitivity in subcutaneous adipose tissue and thermogenic capacity in vivo. *Mol. Metab.* **2020**, *36*, 100965. [[CrossRef](#)]
55. Liu, M.; Lei, H.; Dong, P.; Fu, X.; Yang, Z.; Yang, Y.; Ma, J.; Liu, X.; Cao, Y.; Xiao, R. Adipose-Derived Mesenchymal Stem Cells from the Elderly Exhibit Decreased Migration and Differentiation Abilities with Senescent Properties. *Cell Transplant.* **2017**, *26*, 1505–1519. [[CrossRef](#)] [[PubMed](#)]
56. Zhu, C.; Yu, J.; Pan, Q.; Yang, J.; Hao, G.; Wang, Y.; Li, L.; Cao, H. Hypoxia-inducible factor-2 α promotes the proliferation of human placenta-derived mesenchymal stem cells through the MAPK/ERK signaling pathway. *Sci. Rep.* **2016**, *6*, 35489. [[CrossRef](#)] [[PubMed](#)]
57. Joannes, A.; Brayer, S.; Besnard, V.; Marchal-Sommé, J.; Jaillot, M.; Mordant, P.; Mal, H.; Borie, R.; Crestani, B.; Maillieux, A.A. FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2016**, *310*, L615–L629. [[CrossRef](#)]
58. Yang, Y.; Zeng, Q.S.; Zou, M.; Zeng, J.; Nie, J.; Chen, D.F.; Gan, H.T. Targeting Gremlin 1 Prevents Intestinal Fibrosis Progression by Inhibiting the Fatty Acid Oxidation of Fibroblast Cells. *Front. Pharmacol.* **2021**, *12*, 663774. [[CrossRef](#)]
59. O'Reilly, S.; Ciechomska, M.; Cant, R.; Van Laar, J.M. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor- β (TGF- β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. *J. Biol. Chem.* **2014**, *289*, 9952–9960. [[CrossRef](#)] [[PubMed](#)]
60. Duffy, L.; Henderson, J.; Brown, M.; Pryzborski, S.; Fullard, N.; Summa, L.; Distler, J.H.W.; Stratton, R.; O'Reilly, S. Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis. *Front. Cell Dev. Biol.* **2021**, *9*, 1451. [[CrossRef](#)]
61. O'Reilly, S. Gremlin: A complex molecule regulating wound healing and fibrosis. *Cell. Mol. Life Sci.* **2021**, *78*, 7917–7923. [[CrossRef](#)]
62. Puxeddu, I.; Bader, R.; Piliponsky, A.M.; Reich, R.; Levi-Schaffer, F.; Berkman, N. The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. *J. Allergy Clin. Immunol.* **2006**, *117*, 103–110. [[CrossRef](#)] [[PubMed](#)]
63. Olczyk, P.; Mencner, L.; Komosinska-Vassev, K. The role of the extracellular matrix components in cutaneous wound healing. *Biomed. Res. Int.* **2014**, *2014*, 747584. [[CrossRef](#)]
64. Clark, R.A.F. Biology of Dermal Wound Repair. *Dermatol. Clin.* **1993**, *11*, 647–666. [[CrossRef](#)]
65. Nishikai-Yan Shen, T.; Kado, M.; Hagiwara, H.; Fujimura, S.; Mizuno, H.; Tanaka, R. MMP9 secreted from mononuclear cell quality and quantity culture mediates STAT3 phosphorylation and fibroblast migration in wounds. *Regen. Ther.* **2021**, *18*, 464–471. [[CrossRef](#)]
66. Xue, M.; McKelvey, K.; Shen, K.; Minhas, N.; March, L.; Park, S.Y.; Jackson, C.J. Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. *Rheumatology* **2014**, *53*, 2270–2279. [[CrossRef](#)]
67. Tracy, L.E.; Minasian, R.A.; Caterson, E.J. Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound. *Adv. Wound Care* **2016**, *5*, 119. [[CrossRef](#)]
68. Chen, P.; Parks, W.C. Role of Matrix Metalloproteinases in Epithelial Migration. *J. Cell. Biochem.* **2009**, *108*, 1233. [[CrossRef](#)] [[PubMed](#)]
69. Herrera, I.; Cisneros, J.; Maldonado, M.; Ramírez, R.; Ortiz-Quintero, B.; Anso, E.; Chandel, N.S.; Selman, M.; Pardo, A. Matrix Metalloproteinase (MMP)-1 Induces Lung Alveolar Epithelial Cell Migration and Proliferation, Protects from Apoptosis, and Represses Mitochondrial Oxygen Consumption. *J. Biol. Chem.* **2013**, *288*, 25964–25975. [[CrossRef](#)]
70. Yu, Q.; Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF- β and promotes tumor invasion and angiogenesis. *Genes Dev.* **1999**, *13*, 35–48. [[CrossRef](#)]
71. Cui, Y.; Ji, J.; Hou, J.; Tan, Y.; Han, X. Identification of Key Candidate Genes Involved in the Progression of Idiopathic Pulmonary Fibrosis. *Molecules* **2021**, *26*, 1123. [[CrossRef](#)]
72. Kendall, R.T.; Feghali-Bostwick, C.A. Fibroblasts in fibrosis: Novel roles and mediators. *Front. Pharmacol.* **2014**, *5*, 123. [[CrossRef](#)]
73. Behr, B.; Leucht, P.; Longaker, M.T.; Quarto, N. Fgf-9 is required for angiogenesis and osteogenesis in long bone repair. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 11853–11858. [[CrossRef](#)] [[PubMed](#)]

74. Zhang, J.; Li, Y. Therapeutic uses of FGFs. *Semin. Cell Dev. Biol.* **2016**, *53*, 144–154. [[CrossRef](#)]
75. Frontini, M.J.; Nong, Z.; Gros, R.; Drangova, M.; O'Neil, C.; Rahman, M.N.; Akawi, O.; Yin, H.; Ellis, C.G.; Pickering, J.G. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. *Nat. Biotechnol.* **2011**, *29*, 421–427. [[CrossRef](#)]
76. Wallner, C.; Schira, J.; Wagner, J.M.; Schulte, M.; Fischer, S.; Hirsch, T.; Richter, W.; Abraham, S.; Kneser, U.; Lehnhardt, M.; et al. Application of VEGFA and FGF-9 Enhances Angiogenesis, Osteogenesis and Bone Remodeling in Type 2 Diabetic Long Bone Regeneration. *PLoS ONE* **2015**, *10*, e0118823. [[CrossRef](#)]
77. Farooq, M.; Khan, A.W.; Kim, M.S.; Choi, S. The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration. *Cells* **2021**, *10*, 3242. [[CrossRef](#)]
78. Said, S.S.; O'Neil, C.; Yin, H.; Nong, Z.; Pickering, J.G.; Mequanint, K. Concurrent and Sustained Delivery of FGF2 and FGF9 from Electrospun Poly(ester amide) Fibrous Mats for Therapeutic Angiogenesis. *Tissue Eng.-Part A* **2016**, *22*, 584–596. [[CrossRef](#)]
79. Mitola, S.; Ravelli, C.; Moroni, E.; Salvi, V.; Leali, D.; Ballmer-Hofer, K.; Zammataro, L.; Presta, M. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. *Blood* **2010**, *116*, 3677–3680. [[CrossRef](#)]
80. Corsini, M.; Moroni, E.; Ravelli, C.; Andrés, G.; Grillo, E.; Ali, I.H.; Brazil, D.P.; Presta, M.; Mitola, S. Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 136–145. [[CrossRef](#)]
81. Salcedo, R.; Young, H.A.; Ponce, M.L.; Ward, J.M.; Kleinman, H.K.; Murphy, W.J.; Oppenheim, J.J. Eotaxin (CCL11) Induces In Vivo Angiogenic Responses by Human CCR3+ Endothelial Cells. *J. Immunol.* **2001**, *166*, 7571–7578. [[CrossRef](#)]
82. Park, J.Y.; Kang, Y.W.; Choi, B.Y.; Yang, Y.C.; Cho, B.P.; Cho, W.G. CCL11 promotes angiogenic activity by activating the PI3K/Akt pathway in HUVECs. *J. Recept. Signal Transduct. Res.* **2017**, *37*, 416–421. [[CrossRef](#)] [[PubMed](#)]
83. Ammann, K.R.; DeCook, K.J.; Li, M.; Slepian, M.J. Migration versus proliferation as contributor to in vitro wound healing of vascular endothelial and smooth muscle cells. *Exp. Cell Res.* **2019**, *376*, 58–66. [[CrossRef](#)] [[PubMed](#)]
84. Sottile, J. Regulation of angiogenesis by extracellular matrix. *Biochim. Biophys. Acta* **2004**, *1654*, 13–22. [[CrossRef](#)]
85. Song, Y.H.; Shon, S.H.; Shan, M.; Stroock, A.D.; Fischbach, C. Adipose-derived Stem Cells Increase Angiogenesis through Matrix Metalloproteinase-dependent Collagen Remodeling. *Integr. Biol.* **2016**, *8*, 205. [[CrossRef](#)] [[PubMed](#)]
86. Mazor, R.; Alsaigh, T.; Shaked, H.; Altshuler, A.E.; Pocock, E.S.; Kistler, E.B.; Karin, M.; Schmid-Schönbein, G.W. Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells. *J. Biol. Chem.* **2013**, *288*, 598–607. [[CrossRef](#)] [[PubMed](#)]
87. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T.H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. *Nat. Cell Biol.* **2000**, *2*, 737–744. [[CrossRef](#)]
88. Quintero-Fabián, S.; Arreola, R.; Becerril-Villanueva, E.; Torres-Romero, J.C.; Arana-Argáez, V.; Lara-Riegos, J.; Ramírez-Camacho, M.A.; Alvarez-Sánchez, M.E. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. *Front. Oncol.* **2019**, *9*, 1370. [[CrossRef](#)]
89. Lamalice, L.; Le Boeuf, F.; Huot, J. Endothelial cell migration during angiogenesis. *Circ. Res.* **2007**, *100*, 782–794. [[CrossRef](#)] [[PubMed](#)]
90. Bonanno, E.; Iurlaro, M.; Madri, J.A.; Nicosia, R.F. Type IV collagen modulates angiogenesis and neovessel survival in the rat aorta model. *In Vitro Cell. Dev. Biol. Anim.* **2000**, *36*, 336–340. [[CrossRef](#)]